8-K: Lumexa Imaging Posts Strong Q4, Full-Year 2025 Results

Lumexa Imaging Holdings, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, showing significant revenue and Adjusted EBITDA growth, alongside 2026 guidance.

Summary

• Preliminary unaudited Q4 2025 consolidated revenues are expected to be at least $261 million, an increase from $248.0 million in Q4 2024.
• Preliminary unaudited full-year 2025 consolidated revenues are expected to be at least $1.016 billion, an increase from $948.9 million in 2024.
• Preliminary unaudited Q4 2025 Adjusted EBITDA is expected to be at least $63 million, an increase from $53.7 million in Q4 2024.
• Preliminary unaudited full-year 2025 Adjusted EBITDA is expected to be at least $229 million, an increase from $200.8 million in 2024.
• The Q4 2025 net loss is expected to be not larger than $25.4 million, compared to $25.1 million in Q4 2024.
• The full-year 2025 net loss is expected to be not larger than $43.8 million, a decrease from $94.1 million in 2024.
• Lumexa Imaging completed an initial public offering (IPO) in Q4 2025.
• The company meaningfully reduced leverage and refinanced remaining debt at a more favorable rate in Q4 2025.
• In Q4 2025, 3 wholly owned de novo centers were opened, and one site was acquired.
• For the full year 2025, 9 de novo centers were opened (6 wholly owned and 3 through joint ventures), and one site acquisition was completed.
• Consolidated total procedures increased 4.6% year-over-year to 2,418,096 in 2025.
• System-wide total procedures increased 3.4% year-over-year to 3,972,228 in 2025.
• An AI-powered Breast Arterial Calcification pilot was successfully launched in New Jersey, with over 12% of screening mammography patients electing to add the assessment.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, demonstrating robust financial and operational growth, successful strategic execution, and promising future guidance despite some anticipated public company costs and seasonality.

Positives

• Strong revenue growth: Q4 2025 consolidated revenues expected at least $261 million (up from $248.0 million), full-year 2025 at least $1.016 billion (up from $948.9 million).
• Significant Adjusted EBITDA growth: Q4 2025 expected at least $63 million (up from $53.7 million), full-year 2025 at least $229 million (up from $200.8 million).
• Reduced full-year net loss to not larger than $43.8 million in 2025, a substantial decrease from $94.1 million in 2024.
• Successful completion of an initial public offering (IPO) in Q4 2025.
• Meaningful reduction in leverage and debt refinancing at more favorable rates.
• Robust expansion with 9 de novo centers opened (6 wholly owned, 3 JVs) and one acquisition completed in 2025.
• Strong outpatient volume growth: Consolidated total procedures up 4.6% year-over-year, and advanced procedures up 7.8% year-over-year for full-year 2025.
• System-wide total procedures up 3.4% year-over-year, and advanced procedures up 7.7% year-over-year for full-year 2025.
• Full-year PET volumes increased 17.0% on a consolidated basis and 13.5% on a system-wide basis.
• Successful launch of an AI-powered Breast Arterial Calcification pilot with strong patient adoption (over 12% of screening mammography patients).

Negatives

• Q4 2025 net loss expected not larger than $25.4 million, a slight increase from $25.1 million in Q4 2024.
• The 2026 Adjusted EBITDA guidance includes approximately $7 million in public company costs not incurred in 2025, which lowers the Adjusted EBITDA growth from 7% to 4% at the midpoint.
• Anticipated quarterly seasonality in 2026 related to deductibles resets and annual weather events.

Risks

• The preliminary financial information is unaudited and subject to final review and adjustment, including year-end closing procedures, adjustments, and the completion of the audit.
• Forward-looking statements may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
• The preliminary unaudited results should not be viewed as a substitute for full, audited consolidated financial statements prepared in accordance with GAAP.
• The company has not reconciled its Adjusted EBITDA guidance to GAAP net loss due to the uncertainty and potential variability of certain reconciling items, such as transaction costs, severance, and executive recruiting, which could significantly impact future GAAP net loss.

Future Outlook

Lumexa Imaging expects consolidated revenues for 2026 to be between $1.045 billion and $1.097 billion, and Adjusted EBITDA to be between $234 million and $242 million. This guidance includes approximately $7 million in public company costs not incurred in 2025, which lowers the Adjusted EBITDA growth from 7% to 4% at the midpoint. The company anticipates continued demand for advanced imaging in outpatient settings, growth in its referral base, and solid performance from recent de novo centers. It plans to expand its AI-powered Breast Arterial Calcification technology to other geographies in 2026.

Management Comments

• "Lumexa Imaging delivered strong and consistent fourth quarter results, closing 2025 with solid growth momentum across the platform." Caitlin Zulla, Chief Executive Officer.
• "Expected Adjusted EBITDA growth of at least 14% compared to a year ago was driven by continued demand for advanced imaging in the outpatient setting, growth within our referral base, solid performance of recent de novo centers, and the accelerated ramp following our return in-network with a large payer in New Jersey." Caitlin Zulla, Chief Executive Officer.
• "During 2025, we advanced our disciplined growth strategy by opening a record nine de novo centers, adding a new joint venture partner, and completing one acquisition, expanding our footprint across both joint venture partnerships and our wholly owned markets." Caitlin Zulla, Chief Executive Officer.
• "In 2026, we opened our first de novo in February and experienced quarterly seasonality related to deductibles resets and annual weather events, as included in our annual guidance." Caitlin Zulla, Chief Executive Officer.
• "With favorable industry macro tailwinds of increasing demand for high-quality outpatient imaging, and a focused execution model, we believe Lumexa Imaging is well positioned to deliver sustained growth in 2026." Caitlin Zulla, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Lumexa Imaging's strong performance in outpatient imaging aligns with broader healthcare trends favoring cost-effective, accessible care outside traditional hospital settings. The focus on advanced procedures like MRI, CT, and PET, coupled with AI integration, positions the company to capitalize on technological advancements and increasing demand for specialized diagnostics, particularly in areas like prostate cancer and dementia detection. The expansion through de novo centers and joint ventures reflects a common strategy in the fragmented outpatient imaging market to gain market share and leverage economies of scale.

Comparison to Industry Standards

• StockSavvy.ai assesses Lumexa Imaging's system-wide revenue growth of at least 8% for FY 2025 and projected 2026 consolidated revenue growth (midpoint of $1.071 billion vs $1.016 billion, approximately 5.4%) as competitive within the outpatient imaging sector, which typically sees mid-single-digit growth.
• The company's Adjusted EBITDA growth of at least 14% in Q4 2025 and 7% for FY 2025 (before public company costs) demonstrates strong operational leverage, potentially outperforming some peers facing higher labor or equipment costs.
• The aggressive de novo expansion (9 centers in 2025) indicates a robust growth strategy, comparable to leading outpatient providers like RadNet or Envision Healthcare's imaging divisions, which also pursue organic and inorganic growth to expand geographic reach and service offerings.
• The successful AI-powered Breast Arterial Calcification pilot, with over 12% patient adoption, suggests effective integration of innovative technology, potentially setting a benchmark for patient engagement in preventative health screenings within the industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, successful IPO, debt reduction, and positive 2026 guidance.
• Employees: Continued growth and expansion (de novo centers) may indicate job stability and potential for new opportunities.
• Customers (Patients): Benefit from expanded access to outpatient imaging services, including advanced procedures and new AI-powered diagnostic tools.
• Creditors: Positive impact from reduced leverage and refinanced debt at more favorable rates.
• Joint Venture Partners: Continued expansion through joint ventures indicates ongoing collaboration and potential for shared growth.

Next Steps

• Lumexa Imaging will host a conference call on March 26, 2026, at 8:30 a.m. ET to discuss Q4/FY 2025 financial results and 2026 outlook.
• Expansion of the AI-powered Breast Arterial Calcification technology offering to other geographies in 2026.
• Continued disciplined growth strategy, including opening de novo centers (first in February 2026).
• Further focus on service line expansion strategies, including PET imaging and other clinical innovations.

Key Dates

Recommendation

The filing indicates robust financial performance with significant revenue and Adjusted EBITDA growth, a substantial reduction in net loss, and successful strategic initiatives like the IPO and debt refinancing. The company's expansion through de novo centers and adoption of advanced technologies like AI and PET imaging position it well for sustained future growth in a favorable industry environment. The 2026 guidance, while factoring in public company costs, still projects healthy growth, making it an attractive investment.

Keywords

Outpatient Imaging, Medical Imaging, Healthcare Services, Adjusted EBITDA, Revenue Growth, De Novo Centers, IPO, Debt Refinancing, AI Technology, PET Imaging, Radiopharmaceuticals, Breast Arterial Calcification, Preliminary Results, Financial Guidance, Lumexa Imaging